AbbVie Inc. $ABBV Shares Purchased by Perigon Wealth Management LLC

Perigon Wealth Management LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 3.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 111,108 shares of the company’s stock after buying an additional 3,905 shares during the quarter. Perigon Wealth Management LLC’s holdings in AbbVie were worth $25,726,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its position in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Titleist Asset Management LLC lifted its position in AbbVie by 13.9% in the first quarter. Titleist Asset Management LLC now owns 1,730 shares of the company’s stock worth $362,000 after purchasing an additional 211 shares during the period. Saudi Central Bank bought a new position in AbbVie during the 1st quarter valued at $146,000. Finally, Calton & Associates Inc. increased its position in shares of AbbVie by 73.4% during the 1st quarter. Calton & Associates Inc. now owns 6,176 shares of the company’s stock valued at $1,294,000 after purchasing an additional 2,615 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research analyst reports. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Finally, UBS Group raised their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Trading Up 0.1%

NYSE ABBV opened at $230.07 on Monday. The firm’s 50 day moving average price is $226.73 and its two-hundred day moving average price is $212.72. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market cap of $406.63 billion, a price-to-earnings ratio of 174.30, a PEG ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.